Article Date

On Thursday March 21, bluebird bio will host ISPE colleagues at its Cambridge, MA facility for an evening discussion focused on the company’s innovations in cell and gene therapy.

PM Group is delighted to sponsor this event centered on the approach to and innovations in delivering these therapies to each patient. 

The event will appeal to a wide variety of industry practitioners including process engineers, facilities engineers, and architects, quality assurance, and pogistics professionals. Individuals or organizations involved in the manufacture of cell and gene therapy technologies should attend as the discussion will cover planning, design, quality / regulatory considerations and technology platforms utilized.

Bluebird Bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies. The company develops and brings to market the most advanced products based on the transformative potential of gene therapy.

Having worked with Bluebird bio for over four years, PM Group is currently involved in the design and process engineering for the company’s viral vector manufacturing facility in North Carolina. The company’s groundbreaking work in gene therapy has the potential to treat and cure serious diseases and make a huge difference in patients’ lives.

For more information, visit